Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Maxim Jacobs on Attitude Shift Towards Pharma Products

BTV-Business Television BTV-Business Television, www.b-tv.com
0 Comments| November 1, 2018



Director of Research at Edison Group, Maxim Jacobs speaks on the attitude shift towards pharmaceutical products.

“In other areas, the regulators are getting friendlier to anything associated with the drug culture. For example, psilocybin which is the active ingredient in magic mushrooms. The FDA approved a Phase 2B trial for the treatment of depression. So, things are changing, it’s all very interesting.” – Maxim Jacobs, Director of Research at Edison Group


Symbol:P.CAN



Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.